{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:18:20Z","timestamp":1783397900284,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Exercise therapy (ET) is a valuable adjunctive treatment for rheumatoid arthritis (RA). We hypothesized that ET supports maintenance of remission or low disease activity (LDA) during targeted drug therapy (TT) tapering. This pilot randomized controlled trial evaluated the feasibility, safety, and preliminary effects of individualized ET in RA patients undergoing TT tapering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty-two RA patients initiating TT tapering were randomized to receive personalized ET plus usual care (intervention group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) or usual care alone (control group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) for 16\u2009weeks. The primary exploratory outcome was the proportion of patients maintaining remission or LDA (DAS28-ESR\u2009&lt;\u20093.2) by week 16 without TT re-escalation. Secondary outcomes included DAS28-ESR and its component measurements at weeks 8 and 16, health-related quality of life at week 16 (SF-12), physical activity (IPAQ), and daily step count. Safety and adherence were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All participants in the intervention group completed the 16-week ET program with high adherence. Remission or LDA was maintained in 75.0% (12\/16) of patients in the intervention group and 81.3% (13\/16) in the control group, with no clinically meaningful between-group difference. Although DAS28-ESR scores were comparable, a transient increase in physician visual analog scale was identified in the intervention group at week 8, which returned to the baseline by week 16. Over the 16-week period, IPAQ scores and step count tended to increase after adjustment for baseline values, whereas SF-12 mental health scores declined in the intervention group. No serious adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this pilot randomized controlled trial, individualized ET during TT tapering was safe and feasible. Nevertheless, transient increases in disease activity and declines in mental health indicate the need for careful clinical monitoring and psychological support. The study was not designed to evaluate efficacy outcomes and no clinically meaningful differences between the groups in remission maintenance were identified. Larger trials will be necessary to evaluate the efficacy and long-term safety of ET during TT tapering.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-026-00646-8","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:15:11Z","timestamp":1778667311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trial"],"prefix":"10.1186","volume":"10","author":[{"given":"Shinsuke","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"646_CR1","doi-asserted-by":"crossref","unstructured":"Gwinnutt JM, Wieczorek M, Cavalli G, Balanescu A, Bischoff-Ferrari HA, Boonen A, et al. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022;8(1):e002168.","DOI":"10.1136\/rmdopen-2021-002168"},{"issue":"3","key":"646_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/mr\/roac095","volume":"33","author":"M Torii","year":"2023","unstructured":"Torii M, Itaya T, Minamino H, Katsushima M, Fujita Y, Tanaka H, et al. Management of sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2023;33(3):435\u201340. https:\/\/doi.org\/10.1093\/mr\/roac095.","journal-title":"Mod Rheumatol"},{"issue":"S1","key":"646_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0838.2006.00520.x","volume":"16","author":"BK Pedersen","year":"2006","unstructured":"Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand Med Sci Sports. 2006;16(S1):3\u201363. https:\/\/doi.org\/10.1111\/j.1600-0838.2006.00520.x.","journal-title":"Scand Med Sci Sports"},{"issue":"2","key":"646_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nrrheum.2014.193","volume":"11","author":"FB Benatti","year":"2015","unstructured":"Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases\u2014myokine regulation. Nat Rev Rheumatol. 2015;11(2):86\u201397. https:\/\/doi.org\/10.1038\/nrrheum.2014.193.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"646_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.55563\/clinexprheumatol\/fohyoy","volume":"40","author":"AM Chahardehi","year":"2022","unstructured":"Chahardehi AM, Masoumi SA, Bigdeloo M, Arsad H, Lim V. The effect of exercise on patients with rheumatoid arthritis on the modulation of inflammation. Clin Exp Rheumatol. 2022;40(7):1420\u201331. https:\/\/doi.org\/10.55563\/clinexprheumatol\/fohyoy.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"646_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12979-020-00184-y","volume":"17","author":"SEM Andersson","year":"2020","unstructured":"Andersson SEM, Lange E, Kucharski D, Svedlund S, \u00d6nnheim K, Bergquist M, et al. Moderate- to high intensity aerobic and resistance exercise reduces peripheral blood regulatory cell populations in older adults with rheumatoid arthritis. Immun Ageing. 2020;17(1):12. https:\/\/doi.org\/10.1186\/s12979-020-00184-y.","journal-title":"Immun Ageing"},{"issue":"8","key":"646_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/ard.59.8.615","volume":"59","author":"CH van den Ende","year":"2000","unstructured":"van den Ende CH, Breedveld FC, le Cessie S, Dijkmans BA, de Mug AW, Hazes JM, et al. Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial. Ann Rheumatic Dis. 2000;59(8):615\u201321. https:\/\/doi.org\/10.1136\/ard.59.8.615.","journal-title":"Ann Rheumatic Dis"},{"issue":"5","key":"646_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10067-010-1584-2","volume":"30","author":"B Strasser","year":"2011","unstructured":"Strasser B, Leeb G, Strehblow C, Schobersberger W, Haber P, Cauza E. The effects of strength and endurance training in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30(5):623\u201332. https:\/\/doi.org\/10.1007\/s10067-010-1584-2.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"646_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/art.40899","volume":"71","author":"X Liu","year":"2019","unstructured":"Liu X, Tedeschi SK, Lu B, Zaccardelli A, Speyer CB, Costenbader KH, et al. Long-term physical activity and subsequent risk for rheumatoid arthritis among women: a prospective cohort study. Arthritis Rheumatol. 2019;71(9):1460\u201371. https:\/\/doi.org\/10.1002\/art.40899.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"646_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/art.21165","volume":"53","author":"M Munneke","year":"2005","unstructured":"Munneke M, de Jong Z, Zwinderman AH, Ronday HK, van Schaardenburg D, Dijkmans BAC, et al. Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis. Arthritis Rheum. 2005;53(3):410\u201317. https:\/\/doi.org\/10.1002\/art.21165.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"646_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheumatic Dis. 2017;76(6):960\u201377. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715.","journal-title":"Ann Rheumatic Dis"},{"issue":"9914","key":"646_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","volume":"383","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383(9914):321\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(13)61751-1.","journal-title":"Lancet"},{"issue":"3","key":"646_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2013-203302","volume":"73","author":"K Yoshida","year":"2014","unstructured":"Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheumatic Dis. 2014;73(3):595\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203302.","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"646_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-018-1673-1","volume":"20","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2018;20(1):165. https:\/\/doi.org\/10.1186\/s13075-018-1673-1.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"646_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Educ Chang Biomed Inf. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Educ Chang Biomed Inf"},{"issue":"9","key":"646_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheumatism. 2010, 2010;62(9):2569\u201381. https:\/\/doi.org\/10.1002\/art.27584.","journal-title":"Arthritis Rheumatism"},{"issue":"11","key":"646_CR17","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1177\/0269215517698732","volume":"31","author":"FM Lourenzi","year":"2017","unstructured":"Lourenzi FM, Jones A, Pereira DF, Santos JHCAD, Furtado RNV, Natour J. Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial. Clin Rehabil. 2017;31(11):1482\u201391. https:\/\/doi.org\/10.1177\/0269215517698732.","journal-title":"Clin Rehabil"},{"issue":"1","key":"646_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12891-023-06185-4","volume":"24","author":"A Onishi","year":"2023","unstructured":"Onishi A, Torii M, Hidaka Y, Uozumi R, Oshima Y, Tanaka H, et al. Efficacy of personalized exercise program on physical function in elderly patients with rheumatoid arthritis at high risk for sarcopenia: study protocol for a randomized controlled trial. BMC Musculoskelet Disord. 2023;24(1):280. https:\/\/doi.org\/10.1186\/s12891-023-06185-4.","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"646_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","volume":"14","author":"GAV Borg","year":"1982","unstructured":"Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exercise. 1982;14(5):377\u201381. https:\/\/doi.org\/10.1249\/00005768-198205000-00012.","journal-title":"Med Sci Sports Exercise"},{"issue":"2","key":"646_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheumatism. 1980;23(2):137\u201345. https:\/\/doi.org\/10.1002\/art.1780230202.","journal-title":"Arthritis Rheumatism"},{"issue":"3","key":"646_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333. https:\/\/doi.org\/10.1097\/00005650-199603000-00003.","journal-title":"Med Care"},{"issue":"11","key":"646_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Retailing Clin Epidemiol. 1998;51(11):1037\u201344. https:\/\/doi.org\/10.1016\/S0895-4356(98)00095-X.","journal-title":"J Retailing Clin Epidemiol"},{"issue":"4","key":"646_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11(4):341\u201353. https:\/\/doi.org\/10.1002\/hec.673.","journal-title":"Health Econ"},{"issue":"3 Suppl 2","key":"646_CR24","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13\u201319.","journal-title":"Semin Hematol"},{"key":"646_CR25","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2147\/COPD.S166023","volume":"13","author":"M Ichinose","year":"2018","unstructured":"Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, et al. Efficacy of tiotropium\/olodaterol on lung volume, exercise capacity, and physical activity. COPD. 2018;13:1407\u201319. https:\/\/doi.org\/10.2147\/COPD.S166023.","journal-title":"COPD"},{"key":"646_CR26","doi-asserted-by":"publisher","unstructured":"Craig CL, Marshall AL, Sj\u00f6str\u00f6m M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exercise. 2003;35(8):1381\u201395. https:\/\/doi.org\/10.1249\/01.MSS.0000078924.61453.FB.","DOI":"10.1249\/01.MSS.0000078924.61453.FB"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00646-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:01:49Z","timestamp":1783396909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00646-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00646-8","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Central approval for the study protocol was provided by the Ethics Committee of Osaka Metropolitan University Graduate School of Medicine (approval number: 2022\u2013010), with permission for implementation obtained from all of the participating institutions. The study protocol was registered at UMIN-CTR (registration number: UMIN000049223, registration date: October 17, 2022,\n                      \n                      ) prior to enrollment of the first participants. This study was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Details of the study protocol are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol availability"}},{"value":"There is no identifying information related to the authors, their institutions, funders, or approval committees that might compromise anonymity.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Any other identifying information"}},{"value":"AO has received research grants and speaker fees from Pfizer Inc., Bristol-Myers Squibb, Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., Abbvie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. AO belongs to a department that is financially supported by two pharmaceutical companies (AYUMI Pharmaceutical Co., Asahi Kasei Pharma Corp.). TI has received payments for lectures from JCR Pharmaceuticals and Kyowa Kirin. RU has received personal fees from Daiichi Sankyo, Eisai, Sawai Pharmaceutical, SBI Pharmaceuticals, Statcom, and EPS Corporation, and lecture fees from Janssen Pharmaceuticals and SAS Institute Japan, for work outside of the submitted study. HY has received speaker fees from AbbVie, Asahi Kasei Pharma, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Gilead Sciences, Ono, Pfizer, and Taiho Pharmaceutical. KE is affiliated with the Department of Sports Medical Biomechanics of The Osaka University Graduate School of Medicine, which is supported by Asahi-Kasei. KE has received research grants from Asahi-Kasei and Teijin Pharma. KE has received speaker fees from AbbVie, Amgen, Argenx, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Sanofi, Taisho, Teijin Pharma, and UCB Japan. Y. Okita has received speaker fees from Eli Lilly, Nippon Boehringer Ingelheim Co., Ltd., Pfizer Inc., Asahi Kasei Pharma Corp., Ono Pharmaceutical Co., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Holdings Co., Ltd., and Novartis Pharma. RH has received speaker fees from AbbVie G.K., Asahi Kasei Pharma Co., Eisai Co. Ltd, and Eli Lilly Japan. RW has received a research grant from AbbVie and speaker fees from Asahi-Kasei, Chugai, Eli Lilly, Sanofi, and GSK. TO has received research grants and\/or speaker fees from Abbvie, Asahi Kasei, Chugai, Eisai, Eli Lilly, Tanabe Mitsubishi. Janssen, and Novartis Pharma. MH has received research grants and\/or speaker fees from Abbvie, Asahi Kasei, Astellas, Ayumi, Bristol Meyers, Chugai, EA Pharma, Eisai, Daiichi Sankyo, Eli Lilly, Nihon Shinyaku, Novartis Pharma, and Tanabe Mitsubishi. The remaining authors have no competing interests to declare. None of above-mentioned pharmaceutical companies were involved in the present study design, data collection, data analysis, manuscript writing, or manuscript submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of conflicting interests"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}